Indolent B-Cell Non-Hodgkin Lymphoma Clinical Trials

13 clinical trials for Indolent B-Cell Non-Hodgkin Lymphoma across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma — RECRUITING · PHASE2
• Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab With or Without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab — RECRUITING · PHASE2
• SynKIR-310 for Relapsed/Refractory B-NHL — RECRUITING · PHASE1
• A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL — RECRUITING · PHASE1
• Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma — RECRUITING · PHASE2
• First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma — COMPLETED · PHASE2
• ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases — TERMINATED · PHASE2
• Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma — COMPLETED · PHASE1
• Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy. — OTHER

Refine this search